Myriad Genetics
Edit

Myriad Genetics

http://www.myriad.com/
Last activity: 18.09.2024
Active
Categories: AdTechCareContentDevelopmentDiagnosticsEmployeeHealthTechMedTechPagePersonal
Myriad discovers and commercializes genetic tests that determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs.


As part of our ongoing commitment to you, we will do our best to ensure that the postings on our page are in line with Myriad’s high-quality standards. However, since we unfortunately can’t always monitor every posting or conversation, we expect that our Facebook followers will not post content that falls into the following categories. Myriad reserves the right to remove postings that are:

* abusive, defamatory, threatening or obscene
* fraudulent, deceptive or misleading
* attacking any Myriad Genetics employee by using name or title
* in violation of any intellectual property right of another
* in violation of any law or regulation
* otherwise offensive
* suggestive of new product innovations or advertising ideas
* spam or commercial solicitation

We encourage engaging conversation and appreciate your adherence to our posting guidelines.
Likes
15.84K
Followers
6.73K
Followers
51.78K
Website visits
159.6K /mo.
Mentions
53
Location: United States, Utah, Salt Lake City
Employees: 1001-5000
Phone: +1 800-469-7423
Founded date: 1991

Investors 1

Mentions in press and media 53

DateTitleDescription
18.09.2024Patents for software and genetic code could be revived by two bills in CongressEnlarge / An image from the U.S. Patent and Trademark Office, where in 1874, the newest thing was not software or genetic compositions, but shutter fastenings from H.L. Norton. Andrew Harrer/Bloomberg via Getty Images reader comments 96 The...
06.08.2024Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%). Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second ...
06.08.2024Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%). Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second ...
02.07.2024Myriad Genetics Earns 2024 Great Place To Work® Certification™SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To Work Certification for the second year in a row. ...
02.07.2024Myriad Genetics Earns 2024 Great Place To Work® Certification™SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To Work Certification for the second year in a row. ...
17.06.2024Companion Diagnostics Market Size to Reach $13.74 Billion by 2030: Latest Report by Vantage Market ResearchAccording to a market research study published by Vantage Market Research, the demand analysis of Global Companion Diagnostics Market size revenue was valued at approximately $5.59 Bn in 2022 and is expected to reach around $13.74 Bn by 203...
23.05.2024Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual MeetingMolecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in gene...
06.05.2024Komodo Health & Partners Present 33 Real-World Evidence Research Studies at ISPOR 2024Researchers Used Komodo’s Healthcare Map to Uncover Insights Across Oncology, Women’s Health, Mental Health, Neurology, and more Komodo Insights Power Three Studies Named Finalists for ISPOR 2024 Research Presentation Awards SAN FRANCISCO &...
02.05.2024YourBio Health Congratulates Myriad Genetics on One Million Sales of SneakPeek® Tests Enabled by YourBio's Virtually Painless TAP TechnologyMEDFORD, Mass., May 2, 2024 /PRNewswire/ -- YourBio Health, a Boston-based pioneer in remote, capillary whole blood collection technology, congratulates Myriad Genetics for having sold one million of its leading SneakPeek® Tests. Since 2021...
27.02.2024Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered...Highlights: Full-year testing volume grew 35% year-over-year, or 18% ex-SneakPeek® volume. Full-year 2023 revenue of $753 million, grew 11% year-over-year driven by Prenatal (30%, 15% ex-SneakPeek), Prolaris (21%), Pharmacogenomics (9%), an...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In